Karin Kleinhans
Private Equity Investor at Merck Research Ventures
Profile
Karin Kleinhans is currently a Partner at Merck Research Ventures since 2002 and an Advisor at Berlin Institute of Health since 2021.
She was previously a Director at Cardior Pharmaceuticals GmbH from 2017 to 2022, a Director at Arcum Therapeutics, Inc. from 2021 to 2022, a Director at T-Knife GmbH in 2021, and a Partner at EQT Partners GmbH and LSP Services Deutschland GmbH from 2015 to 2022.
Kleinhans received her undergraduate, graduate, and doctorate degrees from Universität Ulm in 2010 and 2014.
Karin Kleinhans active positions
| Companies | Position | Start |
|---|---|---|
Merck Research Ventures
 Merck Research Ventures Investment ManagersFinance Merck Research Ventures, a subsidiary of Merck Research Laboratories is a venture capital firm founded in 2000. The firm is headquartered in Boston, Massachusetts. | Private Equity Investor | 2001-12-31 |
| Berlin Institute of Health | Consultant / Advisor | 2020-12-31 |
Former positions of Karin Kleinhans
| Companies | Position | End |
|---|---|---|
| EQT Partners GmbH | Private Equity Investor | 2022-12-30 |
Cardior Pharmaceuticals GmbH
 Cardior Pharmaceuticals GmbH Pharmaceuticals: MajorHealth Technology Cardior Pharmaceuticals GmbH develops, manufactures and wholesales drugs. It focuses on the discovery, development and clinical validation of noncoding RNA therapeutics targeting microRNAs as medicines for patients with various forms of heart failure. The company was founded by Sandor Batkai, Claudia Ulbrich, and Thomas Thum on July 21, 2016 and is headquartered in Hannover, Germany. | Director/Board Member | 2022-12-30 |
Arcum Therapeutics, Inc.
 Arcum Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Arcum Therapeutics, Inc. develops pharmaceutical drug products. It provides technologies aim at therapeutic intervention of multidrug-resistant bacterial infections. The company was founded by Paul M. Dunman and is headquartered in Pittsford, NY. | Director/Board Member | 2022-12-30 |
| LSP Services Deutschland GmbH | Private Equity Analyst | 2022-01-01 |
T-Knife GmbH
 T-Knife GmbH BiotechnologyHealth Technology T-Knife GmbH operates as an next-generation adoptive T-cell company using its proprietary humanized T-cell receptor mouse platform to treat solid tumors. The company was founded by Thomas Blankenstein, Elisa Kieback and Holger Specht in 2018 and is headquartered in Berlin, Germany. | Director/Board Member | 2021-12-30 |
Training of Karin Kleinhans
| Universität Ulm | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 7 |
|---|---|
| LSP Services Deutschland GmbH | Finance |
Cardior Pharmaceuticals GmbH
Cardior Pharmaceuticals GmbH Pharmaceuticals: MajorHealth Technology Cardior Pharmaceuticals GmbH develops, manufactures and wholesales drugs. It focuses on the discovery, development and clinical validation of noncoding RNA therapeutics targeting microRNAs as medicines for patients with various forms of heart failure. The company was founded by Sandor Batkai, Claudia Ulbrich, and Thomas Thum on July 21, 2016 and is headquartered in Hannover, Germany. | Health Technology |
| EQT Partners GmbH | Finance |
Merck Research Ventures
Merck Research Ventures Investment ManagersFinance Merck Research Ventures, a subsidiary of Merck Research Laboratories is a venture capital firm founded in 2000. The firm is headquartered in Boston, Massachusetts. | Finance |
| Berlin Institute of Health | |
T-Knife GmbH
T-Knife GmbH BiotechnologyHealth Technology T-Knife GmbH operates as an next-generation adoptive T-cell company using its proprietary humanized T-cell receptor mouse platform to treat solid tumors. The company was founded by Thomas Blankenstein, Elisa Kieback and Holger Specht in 2018 and is headquartered in Berlin, Germany. | Health Technology |
Arcum Therapeutics, Inc.
Arcum Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Arcum Therapeutics, Inc. develops pharmaceutical drug products. It provides technologies aim at therapeutic intervention of multidrug-resistant bacterial infections. The company was founded by Paul M. Dunman and is headquartered in Pittsford, NY. | Health Technology |
- Stock Market
- Insiders
- Karin Kleinhans
